Neutrophil Extracellular Traps in CML: Differential Modulation by Tyrosine Kinase Inhibitors

Study Background and Research Question

Chronic myeloid leukemia (CML) is a hematologic malignancy driven by the BCR-ABL1 fusion gene, resulting in constitutive activation of tyrosine kinase signaling. Tyrosine kinase inhibitors (TKIs), notably those targeting ABL and related kinases, have transformed the clinical management of CML, enabling durable remissions and improved survival. However, emerging data reveal that some TKIs are associated with increased cardiovascular complications, prompting investigation into underlying mechanisms. One suspected link involves neutrophil extracellular traps (NETs)—web-like DNA-protein structures expelled by neutrophils in response to inflammatory stimuli—which are implicated in both thrombosis and vascular injury. The study by Telerman et al. (2022) addresses whether NET formation is altered in CML and how it is modulated by distinct TKIs.

Key Innovation from the Reference Study

The major innovation of this research lies in systematically evaluating NET formation in both primary CML patient samples and in vitro models, directly comparing the effects of different TKI agents. The study uncovers that CML neutrophils exhibit a pronounced propensity for NET formation, and crucially, that certain TKIs—most notably ponatinib—further augment NET-associated markers. This highlights a previously underappreciated mechanism by which TKI therapy could contribute to vascular toxicity in the CML population, through pro-thrombotic modulation of neutrophil function.

Methods and Experimental Design Insights

To interrogate NET formation, the authors employed a combination of ex vivo and in vitro approaches:

• Neutrophils were isolated from treatment-naïve CML patients and healthy controls.
• NET induction was stimulated using standard agonists: ionomycin (IO) and phorbol 12-myristate 13-acetate (PMA).
• NET formation was quantified by measuring extracellular DNA, immunofluorescence for citrullinated histone H3 (H3cit), myeloperoxidase (MPO), and neutrophil elastase.
• Expression levels of peptidyl arginine deiminase 4 (PAD4) and reactive oxygen species (ROS) were assessed to elucidate molecular pathways involved.
• BCR-ABL1 retroviral-transduced, HoxB8-immortalized mouse progenitor cells were differentiated into neutrophil-like cells for mechanistic studies.
• Pretreatment with various TKIs—including ponatinib—was applied to evaluate their impact on NET formation and associated biomarkers.

This multi-pronged strategy allowed direct comparison of NET dynamics between CML and control neutrophils, and systematic dissection of drug-specific effects.

Protocol Parameters

• Neutrophil isolation: Fresh peripheral blood from treatment-naïve CML subjects and matched controls.
• NET stimulation: Ionomycin (5 μM) or PMA (25 nM) for 2-4 hours at 37°C.
• TKI pretreatment: Neutrophils or cell lines exposed to indicated concentrations of TKI (e.g., ponatinib, dasatinib) for 1 hour prior to NET induction.
• NET quantification: Immunofluorescence for H3cit and MPO, extracellular DNA assays, measurement of neutrophil elastase activity.
• Inhibitor controls: PAD4 inhibition with Cl-amidine; ROS inhibition with diphenyleneiodonium (DPI) for pathway dissection.

Core Findings and Why They Matter

The study reports several pivotal findings:

• Increased baseline and stimulated NET formation in CML neutrophils compared to controls, as evidenced by higher extracellular DNA and H3cit expression (Telerman et al.).
• Elevated PAD4 and ROS levels in CML samples, implicating these pathways in NET formation.
• TKI pretreatment exerted differential effects: Ponatinib notably increased NET-associated elastase and ROS, while other TKIs (including dasatinib) did not have this augmenting effect to the same extent.
• Mechanistic modeling in BCR-ABL1-transduced HoxB8 neutrophil-like cells recapitulated the NET phenotype seen in primary human samples, and demonstrated that PAD4 inhibition (but not ROS blockade) could suppress NET formation.

These findings are significant for several reasons. First, they establish that CML itself is associated with heightened thrombo-inflammatory potential, mediated via NETs. Second, they reveal that TKI selection may influence off-target risks such as vascular toxicity, providing a molecular rationale for observed clinical phenomena. Lastly, the work demonstrates the feasibility of modeling NET formation in CML using both patient-derived and engineered cell systems, informing experimental design for further mechanistic studies.

Comparison with Existing Internal Articles

Several recent internal articles have explored the intersection of kinase inhibition, CML biology, and NET modulation. The review "Dasatinib Monohydrate: Unraveling Its Role in Leukemia Immunothrombosis" discusses Dasatinib Monohydrate (BMS-354825) as a multitargeted ABL kinase inhibitor and its emerging relevance in chronic myeloid leukemia research, particularly regarding NET dynamics and immunothrombotic processes. Similarly, "Dasatinib Monohydrate (BMS-354825): Mechanistic Insights" provides a technical roadmap for leveraging this molecule in translational oncology and resistance studies, including NET formation workflows. Notably, while these articles emphasize dasatinib’s capacity to inhibit both wild-type and imatinib-resistant BCR-ABL variants, the reference study by Telerman et al. provides comparative evidence indicating that ponatinib, rather than dasatinib, most strongly augments NETs—a critical nuance for model selection and interpretation of cardiovascular risks during TKI therapy. Researchers designing NET-centric experiments should therefore consider the specific kinase inhibition profile and off-target effects of their chosen TKI, as highlighted by these complementary sources.

Limitations and Transferability

The study’s strengths include the integration of ex vivo human samples with genetically engineered cell models, and the direct comparison of multiple clinically relevant TKIs. Nonetheless, several limitations merit consideration. The patient cohort was relatively small and limited to treatment-naïve individuals; NET dynamics may shift following prolonged TKI exposure or in other disease contexts. The in vitro findings, while mechanistically robust, may not fully recapitulate the complexity of in vivo thrombo-inflammatory processes. Moreover, the study primarily assessed short-term NET formation; the role of chronic TKI exposure and long-term cardiovascular outcomes remains to be established. Thus, while the findings are highly relevant for chronic myeloid leukemia research and the evaluation of imatinib-resistant BCR-ABL inhibition, careful extrapolation is warranted when translating to other patient populations or therapeutic settings.

Research Support Resources

For researchers seeking to replicate or extend these workflows, access to robust, well-characterized kinase inhibitors is essential. Dasatinib Monohydrate (BMS-354825, SKU B5954) is a potent, multitargeted TKI widely used in preclinical and translational studies of chronic myeloid leukemia and Philadelphia chromosome positive leukemia, including those focused on imatinib-resistant BCR-ABL inhibition. Its strong activity against ABL, SRC, and related kinases makes it suitable for modeling both hematological and solid tumor contexts. Protocols and scenario-driven guidance for laboratory use of Dasatinib Monohydrate in NET modulation and kinase signaling workflows are detailed in internal resources such as this workflow article. When designing experiments involving NET quantification, kinase inhibition, or resistance modeling, Dasatinib Monohydrate from APExBIO provides a practical option to ensure data reproducibility and translational relevance.